About ProTA TherapeuticsProTA Therapeutics is a private company established in late 2016 to develop and commercialise treatments for food allergy. The technology is based upon years of research by Prof. Mimi Tang of the Murdoch Children’s Research Institute in Melbourne.
CEO: Dr. Suzanne Lipe
3 articles with ProTA Therapeutics
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
Prota/MCRI Completes Enrolment of Phase 2b Multicentre Clinical Trial of Probiotic Oral Immunotherapy for the Treatment of Peanut Allergy (PPOIT-003)
200 patients have been enrolled and commenced on treatment The multicentre study is being conducted in Melbourne, Adelaide and Perth Treatment will continue through 2019 with top line results expected in the first quarter of 2020
Prota Therapeutics partners with leading global bioscience company, Chr. Hansen, to progress the development of oral immunotherapies to treat food allergies. The partnership will assess the world’s best documented probiotic strain LGG® in a Phase III clinical trial to develop a treatment for peanut allergy.